AKT1S1 Monoclonal Antibody
Know who made it. See the evidence. Buy through one marketplace.
AKT1S1 is a proline-rich substrate of AKT (MIM 164730) that binds 14-3-3 protein (see YWHAH, MIM 113508) when phosphorylated (Kovacina et al., 2003 [PubMed 12524439]).
Packaging image shown for reference. Select a size from the available options.
Fully tested in-house by ABMIUM, or supported by an advanced validation report from a partner reviewed by ABMIUM. Highest confidence. Non-conformities fully supported under the ABMIUM Product Promise.
Quality verified. Independent collaborator or expected-performance data available. Product meets ABMIUM quality standards.
Expected to work based on structural and biochemical data. Not yet directly tested by ABMIUM or a collaborator. No non-conformity support for this combination.
Not recommended for this application or species/sample combination. This may indicate either evidence of unsuitability or that the combination has not been tested and therefore cannot currently be recommended.
Evidence status by application and model.
| Evidence | WB | IHC-p | ICC | ELISA | IHC |
|---|---|---|---|---|---|
| Applications |
This product is manufactured by BT LAB and sold through ABMIUM without relabelling.
ABMIUM supports global orders. Availability, shipping requirements and applicable import arrangements are confirmed before fulfilment where required.
Yes. Send your target, sample, application and experimental conditions through ABMIUM MATCH or technical support.
Unless the listing expressly states otherwise, ABMIUM products are supplied for research use only and are not for diagnostic or therapeutic use.
AKT1S1 (AKT1 substrate 1; PRAS40) encodes proline-rich AKT1 substrate 1, a phosphorylation-sensitive regulator of mechanistic target of rapamycin complex 1 (mTORC1).
Biological function: PRAS40/AKT1S1 negatively regulates mTORC1 by associating with the complex and limiting substrate access under low insulin or nutrient conditions. Insulin- and nutrient-responsive phosphorylation promotes 14-3-3 binding and relief of mTORC1 inhibition.
